news
Positive results for Viking’s rare diseases in vivo study
Viking Therapeutics announced positive initial results from a proof-of-concept study of VK2809 in an in vivo model of glycogen storage disease Ia (GSD Ia).
List view / Grid view
Funding
Drug discovery research is funded primarily by government and by philanthropic groups. Later development is funded mainly by pharmaceutical companies.
news
Wellcome Trust gives Polyphor CHF 2.3 million for antibiotic development
Polyphor has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates.
news
BMBF funds Zika vaccine research group at LMU
The research group will explore novel approaches to vaccine development, focusing on the Zika virus.
news
‘Love hormone’ used a drug lead for inhibiting preterm labour
A team of scientists from Austria, Australia, Denmark, England and the Czech Republic, led by Christian Gruber from the MedUni Vienna's Institute of Pharmacology, managed to isolate a neuropeptide from ants that is very similar to the human love hormone oxytocin, and the closely related hormone vasopressin.
news
Big pharma establishes new industry standards group
Pharma companies involved include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis, and Pfizer.
news
JPND launches €23 million call for neurodegenerative disease research
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
news
Harvard researchers develop multiregional brain-on-a-chip
Harvard University researchers have developed a multiregional brain-on-a-chip that models the connectivity between three distinct regions of the brain.
news
Takeda to acquire ARIAD Pharmaceuticals
The transaction has been approved unanimously by the boards of directors of both companies, and is expected to close by the end of February 2017.
news
Researchers find a potential target for anti-Alzheimer treatments
The USP9 gene has an indirect influence on the so-called tau protein, which is believed to play a significant role in the onset of Alzheimer’s disease.
news
Macrophage raises £9 million & acquires immune-oncology technology
Macrophage Pharma, a newly formed immune-oncology company, has successfully raised £9 million in a Series A equity financing round.
news
Kymab receives $9m R+D grant from Bill & Melinda Gates Foundation
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
news
Kymab secures $100 million Series C funding
1 December 2016 | By Niamh Louise Marriott, Digital Editor
The funds will enable Kymab to advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies, with clinical development in 2017...
news
German Research Foundation (DFG) gives €87 million to fund 20 new research groups
29 November 2016 | By Niamh Louise Marriott, Digital Editor
The Research Training Groups will receive funding of around €87 million for an initial period of four and a half years...
news
Promising antibiotic programme gets European boost
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers at the University of Oxford have been working with two major EU-funded projects to deliver a novel antibiotic programme for clinical development...
news
New scientific fellowship program launched for psoriatic arthritis research
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Five European research institutions have come together in recognition of the need to advance knowledge on the pathophysiology of psoriatic arthritis...